Table 1.
Modulators of OXPHOS in LSCs.
| Drugs | Category | Target | Reference |
|---|---|---|---|
| Antimicrobial tigecycline | FDA-approved | ETC-related protein translation | (11, 27, 29) |
| ddC | – | ETC-related protein translation | (30) |
| A2-32-01 | – | ClpP | (27) |
| ONC201 | Phase I clinical | ClpP | (50, 51) |
| ONC212 | – | ClpP | (52) |
| R2 | NLN | (53) | |
| Cysteine-degrading enzyme | – | Complex II | (34) |
| IACS-010759 | Phase I clinical | Complex I | (33, 56) |
| Mubritinib | – | Complex I | (54) |
| ME-344 | – | Complexes I and III | (55) |
| 8-Cl-Ado | – | ATP synthase | (17) |
| Venetoclax | FDA-approved | BCL2 and DNA methylation | (17, 23, 63, 69) |
| ST1326 | – | FAO | (65, 66) |
| Sorbitan sesquioleate | – | CD36 | (23, 62) |
| Inhibiting NAMPT | – | Nicotinamide metabolism | (69) |